The Role of cMet in Non-Small Cell Lung Cancer Resistant to EGFRInhibitors: Did We Really Find the Target?

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|15|14|1284-1292

ISSN： 1389-4501

Source： Current Drug Targets, Vol.15, Iss.14, 2014-12, pp. : 1284-1292

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer

By  

Current Drug Targets, Vol. 15, Iss. 14, 2014-01 ,pp. : 1263-1272

Bentham Science Publishers

Access to resources Recommend Favorite

The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer

By  

Current Pharmaceutical Design, Vol. 18, Iss. 37, 2012-12 ,pp. : 6155-6168

Bentham Science Publishers

Access to resources Recommend Favorite

Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

By  

Current Pharmaceutical Design, Vol. 19, Iss. 5, 2013-02 ,pp. : 833-840

Bentham Science Publishers

Access to resources Recommend Favorite

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

By Juergens Rosalyn A.   Brahmer Julie R.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 6, 2006-07 ,pp. : 595-600

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite